Early-stage funding for European life sciences companies

We are a venture capital firm specialised in seed investment for innovative early stage companies. BGV generally acts as lead investor. Our current portfolio comprises of biotech developing truly disruptive solutions for high unmet medical needs.

Acerta, a multi-billion Euro success story

BioGeneration was co-founder and investor in the most successful biotech startup in Europe: Acerta Pharma. Acerta Pharma has developed Calquence® (acalabrutinib), a drug now approved by the FDA for the treatment of hematologic malignancies (leukemia). Acerta was sold to AstraZeneca for up to US$ 7 billion in 2016.

Shaping new life-science ventures

We gained our experience from working within small and large pharma and biotech companies. Based on this experience and through our extensive industry network, we are able to bring a range of sector-relevant expertise to help accelerate product development and shape the companies to become attractive investment opportunities for the industry.

Latest news

Synaffix Announces Expansion of Collaboration with ADC Therapeutics

Jul 23, 2020

AMSTERDAM, NETHERLANDS – July 23, 2020 – Synaffix B.V., a biotechnology company focused on enabling antibody-drug conjugates (ADCs) with superior therapeutic index based on its proprietary ADC technology platform, announces that ADC Therapeutics SA has expanded its...

Industry veterans Paul Peter Tak and Eric Meldrum join Citryll’s Board

Jul 21, 2020

Oss, The Netherlands, July 21, 2020 —Citryll announced its Board has been strengthened with twoindustry veterans with impressive track-records, Businesswire Citryll. Paul Peter Tak, MD, PhD served as Professor of Medicine and Chair of the Department of...

Staten Biotechnology, in collaboration with Novo Nordisk, starts dosing of anti-apoC3 antibody SST-5058 in First-in-Human Trial

Jul 21, 2020

Clinical trajectory initiated towards development of novel treatment for dyslipidaemia Nijmegen, The Netherlands, 21 July 2020 – Staten Biotechnology B.V. announced today the initiation of dosing of the Company’s lead asset, STT-5058, in a First-in-Human clinical...

VarmX raises €32 million in Series B financing to develop innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants

Jul 8, 2020

Financing co-led by Ysios Capital and INKEF Capital, joined by Lundbeckfonden Ventures, LSP, and existing investors BioGeneration Ventures and InnovationQuarterProceeds to be used to achieve clinical proof of concept for lead compound, VMX-C001, advance program to...

News overview